Terns Pharmaceuticals Stock Beneish M Score
| TERN Stock | USD 4.69 0.13 2.70% |
Terns | Beneish M Score |
At this time, it appears that Terns Pharmaceuticals is an unlikely manipulator. The earnings manipulation may begin if Terns Pharmaceuticals' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Terns Pharmaceuticals executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Terns Pharmaceuticals' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-4.8
Beneish M Score - Unlikely Manipulator
Terns Pharmaceuticals Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Terns Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Net Receivables | 10.2 M | 11.4 M |
|
| |||||
| Total Assets | 170.3 M | 268.5 M |
|
| |||||
| Total Current Assets | 168.9 M | 267.4 M |
|
| |||||
| Non Current Assets Total | 1.4 M | 1.1 M |
|
| |||||
| Property Plant Equipment | 924 K | 870.5 K |
|
| |||||
| Depreciation And Amortization | 564.5 K | 881 K |
|
| |||||
| Selling General Administrative | 41 M | 39.1 M |
|
| |||||
| Total Current Liabilities | 10.5 M | 11.9 M |
|
| |||||
| Non Current Liabilities Total | 1.1 M | 1.2 M |
|
| |||||
| Short Term Debt | 572.9 K | 603 K |
|
| |||||
| Gross Profit Margin | 0.39 | 0.44 |
|
|
Terns Pharmaceuticals Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Terns Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Terns Pharmaceuticals in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Terns Pharmaceuticals' degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals
About Terns Pharmaceuticals Beneish M Score
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization |
|
Terns Pharmaceuticals Earnings Manipulation Drivers
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Terns Pharmaceuticals. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 23.9M | 92.3M | 168.1M | 287.0M | 268.5M | 170.3M | |
| Total Current Assets | 22.2M | 90.9M | 166.9M | 285.2M | 267.4M | 168.9M | |
| Non Current Assets Total | 1.7M | 1.4M | 1.1M | 1.8M | 1.1M | 1.4M | |
| Property Plant Equipment | 961K | 1.2M | 1.0M | 757K | 870.6K | 924K | |
| Depreciation And Amortization | 195K | 394K | 512K | 1.0M | 881K | 564.5K | |
| Selling General Administrative | 8.7M | 9.0M | 19.5M | 22.4M | 39.1M | 41.0M | |
| Total Current Liabilities | 5.0M | 22.8M | 6.8M | 8.5M | 11.9M | 10.5M | |
| Non Current Liabilities Total | 14.7M | 877K | 947K | 1.6M | 1.2M | 1.1M | |
| Net Debt | (12.3M) | (62.0M) | (47.7M) | (142.0M) | (79.3M) | (83.3M) | |
| Operating Income | (70.2M) | (37.0M) | (49.9M) | (62.0M) | (102.6M) | (97.4M) | |
| Total Cash From Operating Activities | (66.2M) | (29.8M) | (41.8M) | (49.1M) | (67.7M) | (71.1M) | |
| Investments | (3.0M) | 7.3M | (119.4M) | (22.0M) | (38.0M) | (39.9M) | |
| Short Term Investments | 7.3M | 0.0 | 118.3M | 139.9M | 183.5M | 192.7M |
About Terns Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Terns Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Terns Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Terns Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Terns Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Terns Pharmaceuticals' short interest history, or implied volatility extrapolated from Terns Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock:Check out Terns Pharmaceuticals Piotroski F Score and Terns Pharmaceuticals Altman Z Score analysis. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Terns Stock analysis
When running Terns Pharmaceuticals' price analysis, check to measure Terns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Terns Pharmaceuticals is operating at the current time. Most of Terns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Terns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Terns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Terns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
Is Terns Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 0.035 | Return On Assets (0.23) | Return On Equity (0.34) |
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.